JP Morgan Maintains Overweight on Cellebrite DI, Raises Price Target to $14
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Essex maintains an Overweight rating on Cellebrite DI (NASDAQ:CLBT) and raises the price target from $12 to $14.
May 24, 2024 | 2:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Brian Essex maintains an Overweight rating on Cellebrite DI and raises the price target from $12 to $14.
The Overweight rating and increased price target from a reputable analyst at JP Morgan is likely to positively impact investor sentiment and drive short-term price appreciation for CLBT.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100